FY2030 Earnings Forecast for Agenus Issued By HC Wainwright

Agenus Inc. (NASDAQ:AGEN) – Stock analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Agenus in a research note issued on Thursday, January 15th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will post earnings per share of $0.34 for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported $1.94 earnings per share for the quarter, missing the consensus estimate of $2.63 by ($0.69). The business had revenue of $30.24 million for the quarter, compared to analysts’ expectations of $80.39 million.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $14.50.

Agenus Price Performance

AGEN opened at $3.37 on Monday. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34. The firm has a market capitalization of $114.61 million, a PE ratio of -1.58 and a beta of 1.58. The company’s 50-day moving average is $3.86 and its 200 day moving average is $4.38.

Hedge Funds Weigh In On Agenus

Several institutional investors have recently modified their holdings of the business. Marshall Wace LLP purchased a new stake in shares of Agenus during the second quarter valued at approximately $1,976,000. AQR Capital Management LLC grew its stake in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after purchasing an additional 427,604 shares during the period. Bank of America Corp DE increased its position in shares of Agenus by 110.0% during the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after purchasing an additional 220,327 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Agenus during the 2nd quarter worth $906,000. Finally, Raymond James Financial Inc. raised its stake in shares of Agenus by 16,654.0% during the 3rd quarter. Raymond James Financial Inc. now owns 145,760 shares of the biotechnology company’s stock worth $561,000 after purchasing an additional 144,890 shares during the period. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.